4.7 Article

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Microbiology

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019

James A. Karlowsky et al.

Summary: This study reports the in vitro susceptibility data of Gram-negative clinical isolates from North America and Europe to cefiderocol and comparators. The results indicate that clinical isolates collected from 2014 to 2019 in North America and Europe were highly susceptible to cefiderocol.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Article Immunology

Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece

Dimitra Petropoulou et al.

Summary: This study evaluated the in vitro activity of the sulbactam-durlobactam (SD) combination against carbapenem-resistant A. baumannii isolates. SD demonstrated the lowest minimum inhibitory concentration (MIC90) and showed potential utility for the treatment of infections caused by A. baumannii. The addition of imipenem further enhanced the activity of SD.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)

Article Infectious Diseases

Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study

T. Kostyanev et al.

Summary: This study investigated the phenotypic and molecular characteristics of carbapenem-resistant Acinetobacter baumannii isolates from the EURECA clinical trial. The isolates mainly harbored bla(OXA-23) or blaOXA-72 genes, with the majority belonging to international clone II and showing high diversity.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)

Review Microbiology

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam

Adam B. Shapiro et al.

Summary: The combination of durlobactam and sulbactam effectively inhibits multidrug-resistant Acinetobacter strains, enhancing the clinical utility of sulbactam.

FRONTIERS IN MICROBIOLOGY (2021)

Article Infectious Diseases

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Qiwen Yang et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

Article Infectious Diseases

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Harald Seifert et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

Review Microbiology

New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

Burcu Isler et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Review Microbiology

Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges

Darren Wong et al.

CLINICAL MICROBIOLOGY REVIEWS (2017)

Article Microbiology

Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii

William F. Penwell et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)

Review Infectious Diseases

Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology

Anais Potron et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)

Article Chemistry, Multidisciplinary

Distinctive Attributes of β-Lactam Target Proteins in Acinetobacter baumannii Relevant to Development of New Antibiotics

Seungil Han et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)